Skip to content

Released Mar 27, 2023, before the open

10-K filed Mar 27, 2023, 86 days after period end · 0001576885-23-000017

Q4 2022 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$12.87MderivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$14,249,000N/M
Operating Cash Flowderived-$11,203,000N/M
Free Cash Flowderived-$11,238,000N/M

What the release said

The release

Same quarter

MetricQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figures
Net Income-$12.87M-$8.35M—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR